ASH Annual Meeting & Exposition

7-10 December 2019 ASH Annual Meeting & Exposition Orlando, FL, USA

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma. Nastoupil L.J., Neelapu S.S., Davis E., Samaniego F., Fowler N.H., Westin J.R., Lee H.J., Wang M., Hagemeister F.B., Cecil A.R.L., Dow J., McHale D., Silva F., […]

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH

Oxfordshire, UK, 4 December 2019 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of […]